2023 World Conference on Lung Cancer (Posters)-P2.14. Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial

P2.14. Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial - PDF(Abstract)

Back to course

Pdf Summary

This document presents the updated results of a phase II trial evaluating the efficacy and safety of camrelizumab (PD-1 antibody) combined with nab-paclitaxel and carboplatin as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The trial included 60 patients who received 46 cycles of camrelizumab, nab-paclitaxel, and carboplatin followed by maintenance therapy with camrelizumab. The primary endpoint was progression-free survival (PFS) rate at 6 months. <br /><br />The results showed that 51 out of 55 patients achieved an objective response, with 1 complete response, 41 confirmed partial responses, and 9 unconfirmed partial responses. The confirmed objective response rate was 76.3% and the unconfirmed objective response rate was 92.7%. The disease control rate was 98.2%. The median duration of response was 6.8 months. <br /><br />The 6-month PFS rate was 50% and the median PFS was 6.03 months. The median overall survival was 18.3 months. <br /><br />In terms of safety, 34% of patients experienced grade 3 or 4 adverse events, with the most common being neutropenia, leukopenia, thrombocytopenia, bilirubin increase, and gamma-glutamyl transferase increase. <br /><br />In conclusion, the combination of camrelizumab, nab-paclitaxel, and carboplatin demonstrated promising efficacy and a manageable safety profile as first-line treatment for ES-SCLC. This study provides further evidence for the use of immunotherapy in combination with chemotherapy for the treatment of ES-SCLC.

Asset Subtitle

Shengxiang Ren

Meta Tag

Speaker Shengxiang Ren

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

phase II trial

efficacy

safety

camrelizumab

nab-paclitaxel

carboplatin

ES-SCLC

objective response

PFS rate

adverse events